the pleiotropic effects of paricalcitol: beyond bone-mineral metabolism
Clicks: 187
ID: 239279
2016
Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD.
| Reference Key |
egido2016nefrologathe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Jesús Egido;Alberto Martínez-Castelao;Jordi Bover;Manuel Praga;José Vicente Torregrosa;Elvira Fernández-Giráldez;Carlos Solozábal |
| Journal | demiryolu mühendisliği |
| Year | 2016 |
| DOI | 10.1016/j.nefroe.2016.02.006 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.